Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review.pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Abbott, Exact Sciences, Cologuard, Oncotype DX, Novo Nordisk, Wegovy HD, semaglutide,orforglipron, Eli Lilly, GSK, Lynavoy, linerixibat, PBC, Pfizer, talazoparib, TALAPRO-3, prostate cancer, camrelizumab, rivoceranib, HCC, Rhythm Pharmaceuticals, Imcivree, Novartis, PI3K, Genentech, emugrobart, RocketPharmaceuticals, Kresladi, Lantheus, AAD 2026, M&A, obesity, GLP-1, diagnostics, Lilly
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →